Veeva Systems Inc
NYSE:VEEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (47.1), the stock would be worth $375.56 (124% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 21.1 | $167.79 |
0%
|
| 3-Year Average | 47.1 | $375.56 |
+124%
|
| 5-Year Average | 49.4 | $393.43 |
+134%
|
| Industry Average | 12.9 | $102.65 |
-39%
|
| Country Average | 14.4 | $114.36 |
-32%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$21.9B
|
/ |
Feb 2026
$985m
|
= |
|
|
$21.9B
|
/ |
Jan 2027
$1.7B
|
= |
|
|
$21.9B
|
/ |
Jan 2028
$1.9B
|
= |
|
|
$21.9B
|
/ |
Jan 2029
$2.1B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
27.5B USD | 21.1 | 30.2 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
15.1B AUD | 78 | 63 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 10.1 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.1B SEK | -131.6 | 95 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
5B USD | 15.4 | 43.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 14.8 | 18.7 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.2B CNY | -121.8 | -62.4 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.7B USD | 0 | 0 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
245.4B INR | 24.3 | 36.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Veeva Systems Inc
Glance View
Veeva Systems Inc., born in the heart of Silicon Valley in 2007, embarked on its journey with a clear mission: to revolutionize the pharmaceutical and life sciences industries with cloud-based solutions. Founded by Peter Gassner, who previously held leadership roles at Salesforce and PeopleSoft, Veeva identified a niche opportunity amid the highly-regulated, complex landscape of healthcare. The company began by offering Customer Relationship Management (CRM) software tailored for the life sciences sector, allowing clients to stay compliant with industry regulations while efficiently managing relationships across the intricate healthcare network. Veeva’s CRM solutions gradually became instrumental for pharmaceutical and biotech companies in conducting their marketing, sales, and collaboration activities. As Veeva expanded, it diversified its portfolio by delving into other digital solutions, such as data management and analytics, content management, and regulatory and compliance software. Its Vault platform stood out, providing a unified suite for managing a vast array of business processes and content across powerful cloud applications. This approach enabled Veeva to serve its clientele throughout the drug development lifecycle, from research and development to commercialization. By adopting a subscription-based pricing model, Veeva ensured a steady revenue stream while continuously enhancing its offerings, solidifying its position as both a trusted partner and a critical component of its clients’ operational infrastructure. Through these strategic expansions, Veeva Systems Inc. not only adapted to the evolving demands of the healthcare sector but also reinforced its dominance in the specialized domain of life sciences cloud technology.
